The Antibody Contract Development & Manufacturing Organization market is segmented by product into monoclonal antibodies, polyclonal antibodies, and antibody fragments. Monoclonal antibodies are expected to dominate the market, owing to their high specificity and targeted therapy capabilities.
2. Source
Based on source, the market is segmented into mammalian cells, microbial cells, and others. Mammalian cell-derived antibodies are anticipated to witness significant growth, attributed to their ability to produce complex proteins with proper post-translational modifications.
3. Therapeutic Area
In terms of therapeutic area, the Antibody CDMO market is divided into oncology, neurology, cardiology, and others. The oncology segment is projected to hold the largest market share, driven by the rising prevalence of cancer and the increasing demand for personalized medicine.
4. End-use
The end-use segment includes pharmaceutical & biotechnology companies, academic & research institutes, and others. Pharmaceutical & biotechnology companies are expected to be the major end-users of Antibody CDMO services, owing to the rising outsourcing of manufacturing activities to CDMOs for cost-effectiveness and expertise.